Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein. PATIENTS AND METHODS: In this multicenter, double-blind, phase III study, 418 patients with previously u...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Robert, Caroline, Long, Georgina V., Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Rutkowski, Piotr, Hassel, Jessica C., McNeil, Catriona M., Kalinka, Ewa Anna, Lebbé, Céleste, Charles, Julie, Hernberg, Micaela M., Savage, Kerry J., Chiarion-Sileni, Vanna, Mihalcioiu, Catalin, Mauch, Cornelia, Arance, Ana, Cognetti, Francesco, Ny, Lars, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Zoco, Jesús, Re, Sandra, Ascierto, Paolo A., Atkinson, Victoria
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676881/
https://ncbi.nlm.nih.gov/pubmed/32997575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00995
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados